As of 2026-06-26, Aktis Oncology, Inc. Common stock (AKTS) has a 3-month relative strength percentile of 93 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.2%, relative volume 3.61×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
AKTS is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
AKTS currently shows a 20-day average daily range (ADR%) of 9.2%, a 90-day beta versus the S&P 500 of 1.67. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes AKTS's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what AKTS has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
AKTS most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-11. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
10y · since 2022
Best monthJanon averageavg +18111.70% · 67% win · n 3
Worst monthSepon averageavg -23.86% · 33% win · n 3